Literature DB >> 25311500

Assessment of human effective absorbed dose of 67 Ga-ECC based on biodistribution rat data.

Saeed Shanehsazzadeh1, Hassan Yousefnia, Afsaneh Lahooti, Samaneh Zolghadri, Amir Reza Jalilian, Hossien Afarideh.   

Abstract

OBJECTIVE: In a diagnostic context, determination of absorbed dose is required before the introduction of a new radiopharmaceutical to the market to obtain marketing authorization from the relevant agencies. In this work, the absorbed dose of [67 Ga]-ethylenecysteamine cysteine [(67 Ga)ECC] to human organs was determined by using distribution data for rats.
METHODS: For biodistribution data, the animals were sacrificed by CO2 asphyxiation at selected times after injection (0.5, 2 and 48 h, n = 3 for each time interval), then the tissue (blood, heart, lung, brain, intestine, feces, skin, stomach, kidneys, liver, muscle and bone) were removed. The absorbed dose was determined by Medical Internal Radiation Dose (MIRD) method after calculating cumulated activities in each organ.
RESULTS: Our prediction shows that a 185-MBq injection of (67)Ga-ECC into the humans might result in an estimated absorbed dose of 0.029 mGy in the whole body. The highest absorbed doses are observed in the spleen and liver with 33.766 and 16.847 mGy, respectively.
CONCLUSION: The results show that this radiopharmaceutical can be a good SPECT tracer since it can be produced easily and also the absorbed dose in each organ is less than permitted absorbed dose.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25311500     DOI: 10.1007/s12149-014-0917-7

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  3 in total

1.  Preparation and Evaluation of (68)Ga-ECC as a PET Renal Imaging Agent.

Authors:  Alireza Mirzaei; Amir Reza Jalilian; Ayuob Aghanejad; Mohammad Mazidi; Hassan Yousefnia; Gholamali Shabani; Khosro Ardaneh; Parham Geramifar; Davood Beiki
Journal:  Nucl Med Mol Imaging       Date:  2015-02-24

2.  Preparation, Biological Evaluation and Dosimetry Studies of 175Yb-Bis-Phosphonates for Palliative Treatment of Bone Pain.

Authors:  Ashraf Fakhari; Amir R Jalilian; Hassan Yousefnia; Saeed Shanehsazzadeh; Ali Bahrami Samani; Fariba Johari Daha; Mehdi Shafiee Ardestani; Ali Khalaj
Journal:  Mol Imaging Radionucl Ther       Date:  2015-10-05

3.  Development of 153Sm-DTPA-SPION as a theranostic dual contrast agents in SPECT/MRI.

Authors:  Amir Gholami; Seyyed Hossein Mousavie Anijdan
Journal:  Iran J Basic Med Sci       Date:  2016-10       Impact factor: 2.699

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.